News & Updates

The visceral fat area (VFA) index and visceral fat density (VFD) are independently related to the prevalence of nonalcoholic fatty liver disease (NAFLD), according to a study. However, the VFD appears to have a stronger link to the incidence of NAFLD than the VFA index.

Supplementation with vitamin D, particularly at the lower dosage of 600 IU/day, appears to confer positive effects on high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol, with significant changes persisting after the supplementation period, a study has shown.

Adherence to medium-dose spice diet (MSD) for 4 weeks results in a reduction of fasting plasma interleukin (IL)-6 and postprandial plasma IL-11β, IL-8, and tumour necrosis factor alpha (TNF-α) as well as changes in monocyte function in adults at risk of cardiometabolic disease, a study has shown.

Moderate-intensity stair walking, even bouts as short as 3 minutes, can lower postprandial blood glucose and insulin levels, as shown in a study. However, longer bouts are needed to be beneficial for insulin sensitivity.

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.